Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
It is a single-center, open, single-arm, non-randomized investigator-initiated trial
evaluating the efficacy and safety of recombinant adeno-associated virus administration for
patients with Menkes syndrome.
Phase:
Early Phase 1
Details
Lead Sponsor:
Kunming Hope of Health Hospital
Collaborator:
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China